Trial Profile
A phase 3, placebo-controlled, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of K-333 (peretinoin) in patients with complete cure of hepatocellular carcinoma in Asia
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Peretinoin (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Kowa
- 02 May 2018 Planned End Date changed from 31 Jan 2019 to 30 Apr 2021.
- 09 Jan 2018 Planned End Date changed from 30 Mar 2018 to 31 Jan 2019.
- 31 Jan 2017 Status changed from recruiting to active, no longer recruiting.